| Type 2 diabetes and its impact on the immune system A Berbudi, N Rahmadika, AI Tjahjadi, R Ruslami Current diabetes reviews 16 (5), 442-449, 2020 | 930 | 2020 |
| Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial R Ruslami, AR Ganiem, S Dian, L Apriani, TH Achmad, AJ van der Ven, ... The Lancet infectious diseases 13 (1), 27-35, 2013 | 400 | 2013 |
| Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults D Menzies, M Adjobimey, R Ruslami, A Trajman, O Sow, H Kim, ... New England Journal of Medicine 379 (5), 440-453, 2018 | 368 | 2018 |
| Implications of the global increase of diabetes for tuberculosis control and patient care R Ruslami, RE Aarnoutse, B Alisjahbana, AJAM Van Der Ven, ... Tropical Medicine & International Health 15 (11), 1289-1299, 2010 | 366 | 2010 |
| Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes HMJ Nijland, R Ruslami, JE Stalenhoef, EJ Nelwan, B Alisjahbana, ... Clinical Infectious Diseases 43 (7), 848-854, 2006 | 327 | 2006 |
| Clinical management of concurrent diabetes and tuberculosis and the implications for patient services AL Riza, F Pearson, C Ugarte-Gil, B Alisjahbana, S Van de Vijver, ... The lancet Diabetes & endocrinology 2 (9), 740-753, 2014 | 244 | 2014 |
| Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients R Ruslami, HMJ Nijland, B Alisjahbana, I Parwati, R van Crevel, ... Antimicrobial agents and chemotherapy 51 (7), 2546-2551, 2007 | 234 | 2007 |
| Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis HJ Nijland, R Ruslami, AJ Suroto, DM Burger, B Alisjahbana Clin. Infect. Dis 45, 1001-1007, 0 | 190* | |
| Safety and side effects of rifampin versus isoniazid in children T Diallo, M Adjobimey, R Ruslami, A Trajman, O Sow, J Obeng Baah, ... New England Journal of Medicine 379 (5), 454-463, 2018 | 167 | 2018 |
| Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes R Ruslami, HMJ Nijland, IGN Adhiarta, SHKS Kariadi, B Alisjahbana, ... Antimicrobial agents and chemotherapy 54 (3), 1068-1074, 2010 | 165 | 2010 |
| GeneXpert MTB/Rif to diagnose tuberculous meningitis: perhaps the first test but not the last NC Bahr, S Marais, M Caws, R Van Crevel, RJ Wilkinson, JS Tyagi, ... Clinical Infectious Diseases 62 (9), 1133-1135, 2016 | 129 | 2016 |
| Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients E Burhan, C Ruesen, R Ruslami, A Ginanjar, H Mangunnegoro, ... Antimicrobial agents and chemotherapy 57 (8), 3614-3619, 2013 | 118 | 2013 |
| Diabetes mellitus among pulmonary tuberculosis patients from 4 tuberculosis-endemic countries: the TANDEM study C Ugarte-Gil, B Alisjahbana, K Ronacher, AL Riza, RC Koesoemadinata, ... Clinical Infectious Diseases 70 (5), 780-788, 2020 | 102 | 2020 |
| Clinical Parameters, Routine Inflammatory Markers, and LTA4H Genotype as Predictors of Mortality Among 608 Patients With Tuberculous Meningitis in Indonesia A van Laarhoven, S Dian, C Ruesen, E Hayati, MSMA Damen, J Annisa, ... The Journal of infectious diseases 215 (7), 1029-1039, 2017 | 97 | 2017 |
| Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis KE Stott, H Pertinez, MGG Sturkenboom, MJ Boeree, R Aarnoutse, ... Journal of Antimicrobial Chemotherapy 73 (9), 2305-2313, 2018 | 94 | 2018 |
| Standardized methods for enhanced quality and comparability of tuberculous meningitis studies BJ Marais, AD Heemskerk, SS Marais, R van Crevel, U Rohlwink, M Caws, ... Clinical Infectious Diseases 64 (4), 501-509, 2017 | 94 | 2017 |
| Improving the microbiological diagnosis of tuberculous meningitis: a prospective, international, multicentre comparison of conventional and modified Ziehl–Neelsen stain … AD Heemskerk, J Donovan, S Marais, L Chaidir, VTM Dung, CM Centner, ... Journal of Infection 77 (6), 509-515, 2018 | 93 | 2018 |
| Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis L Te Brake, S Dian, AR Ganiem, C Ruesen, D Burger, R Donders, ... International journal of antimicrobial agents 45 (5), 496-503, 2015 | 93 | 2015 |
| Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study A van Laarhoven, S Dian, R Aguirre-Gamboa, J Avila-Pacheco, ... The Lancet Infectious Diseases 18 (5), 526-535, 2018 | 84 | 2018 |
| Latent tuberculosis infection in healthcare workers in low-and middle-income countries: an updated systematic review L Apriani, S McAllister, K Sharples, B Alisjahbana, R Ruslami, PC Hill, ... European Respiratory Journal 53 (4), 2019 | 78 | 2019 |
Bachti AlisjahbanaUniversitas PadjadjaranEmail yang diverifikasi di unpad.ac.id
